X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kezar Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2023
Details:
Under the agreement, Everest will develop and commercialize KZR-616 (zetomipzomib), Kezar’s novel, first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea and Southeast Asia.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: $132.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2023
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
KZR-616 (zetomipzomib), a first-in-class inhibitor of the immunoproteasome, has potent anti-inflammatory effects. Zetomipzomib continued to be well-tolerated over the course of the 37-week study, demonstrating a favorable safety and tolerability profile.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
The MISSION Phase 2 topline results show a clinically meaningful overall renal response to KZR-616 (zetomipzomib) after 6 months, without high-dose induction therapy. Patients in the trial also experienced reductions in extra-renal manifestations of lupus.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
KZR-616 (zetomipzomib) demonstrated a favorable safety and tolerability profile, including in the PRESIDIO Open-label Extension Study where weekly zetomipzomib has been administered for up to an additional 77 weeks.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN).
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Proceeds from the transaction will be used for general growth capital and for further advancement of the Company’s clinical candidates, KZR-616 and KZR-261.
Lead Product(s): Zetomipzomib
Therapeutic Area: Musculoskeletal Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 10, 2021
Details:
KZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
KZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
KZR-616 is a first-in-class selective immunoproteasome inhibitor with the potential to impact multiple drivers of immune-mediated diseases and inflammation. PRESIDIO is a Phase 2 placebo-controlled cross-over trial to evaluate KZR-616 for the treatment of PM and DM.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
Results from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) were presented at the Pan-American Congress of Rheumatology.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Kezar intends to use the net proceeds from the offering primarily to fund the research and development of its product candidates, acquire or license products or technologies that are complementary to its own.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $46.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 08, 2020
Details:
Overall, improvements were seen across 7 measures of disease activity, and 2 of 2 patients with lupus nephritis experienced a greater than 50% reduction in proteinuria. A positive safety and tolerability profile was observed with step-up dosing of KZR-616.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
The presentations will highlight results from preclinical evaluation of KZR-261 and results from the first 4 cohorts of the MISSION Study evaluating KZR-616 for treatment of SLE.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Kezar anticipate delays in their previously anticipated clinical development and data release milestones for KZR-616. However, Phase 1b portion of their MISSION study will continue to receive data.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
Kezar intends to use the net proceeds from the offering primarily to fund the research and development of its product candidates, acquire or license products or technologies.
Lead Product(s): Zetomipzomib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $56.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
